pulmonari
tuberculosi
tb
remain
seriou
health
problem
worldwid
effect
vaccin
strategi
need
report
develop
novel
tb
vaccin
use
vesicular
stomat
viru
vsv
viral
vector
system
express
shown
immunogen
given
mice
either
intranas
intramuscular
im
rout
although
distinct
tcell
profil
result
rout
immun
intranas
deliveri
gener
mucos
tcell
respons
protect
upon
pulmonari
mycobacterium
tuberculosi
mtb
challeng
protect
manifest
earli
timepoint
immun
sustain
potenti
use
mucos
booster
parenter
prime
adenovir
tb
vaccin
express
investig
immun
markedli
boost
antigenspecif
tcell
respons
airway
lumen
also
augment
immun
activ
system
compart
prime
translat
significantli
better
protect
efficaci
pulmonari
challeng
mtb
either
vaccin
use
alon
studi
therefor
suggest
vsv
vector
system
promis
candid
use
heterolog
viral
primeboost
immun
regimen
intracellular
bacteri
infect
pulmonari
tuberculosi
tb
remain
seriou
health
problem
worldwid
effect
vaccin
strategi
need
report
develop
novel
tb
vaccin
use
vesicular
stomat
viru
vsv
viral
vector
system
express
shown
immunogen
given
mice
either
intranas
intramuscular
im
rout
although
distinct
tcell
profil
result
rout
immun
intranas
deliveri
gener
mucos
tcell
respons
protect
upon
pulmonari
mycobacterium
tuberculosi
mtb
challeng
protect
manifest
earli
timepoint
immun
sustain
potenti
use
mucos
booster
parenter
prime
adenovir
tb
vaccin
express
investig
immun
markedli
boost
antigenspecif
tcell
respons
airway
lumen
also
augment
immun
activ
system
compart
prime
translat
significantli
better
protect
efficaci
pulmonari
challeng
mtb
either
vaccin
use
alon
studi
therefor
suggest
vsv
vector
system
promis
candid
use
heterolog
viral
primeboost
immun
regimen
intracellular
bacteri
infect
tuberculosi
tb
continu
remain
major
threat
health
global
approxim
onethird
world
popul
infect
mycobacterium
tuberculosi
mtb
infect
individu
mount
strong
cellmedi
immun
respons
restrict
diseas
dormant
state
eventu
develop
activ
tb
approxim
million
individu
succumb
diseas
year
make
tb
one
deadli
infecti
diseas
world
diseas
predominantli
affect
popul
develop
countri
view
fact
incid
infect
multidrugresist
extens
drugresist
strain
mtb
rise
effect
practic
mean
combat
tb
vaccin
bacil
bcg
current
tb
vaccin
use
sinc
billion
individu
immun
date
despit
extens
use
efficaci
bcg
remain
controversi
although
effect
protect
sever
childhood
form
tb
protect
adult
pulmonari
tb
rang
explain
current
tb
epidem
therefor
recogn
need
develop
new
tb
vaccin
among
major
novel
tb
vaccin
formul
viral
vector
system
includ
adenoviru
ad
modifi
vaccinia
viru
ankara
poxviru
influenza
viru
viralvector
tb
vaccin
evalu
standalon
vaccin
booster
heterolog
primeboost
regimen
comparison
viral
system
recombin
adenovir
vaccin
system
possess
advantag
establish
safeti
wellcharacter
vectorolog
transgen
express
potenc
inde
recombin
human
type
ad
express
develop
lab
shown
immuneprotect
follow
singl
immun
murin
model
howev
potenti
drawback
viral
system
initi
immun
host
gener
strong
neutral
antibodi
respons
viral
backbon
limit
efficaci
repeat
immun
viral
vaccin
purpos
immun
boost
mind
develop
novel
vesicular
stomat
viru
vsv
vector
tb
vaccin
evalu
potenti
booster
amplifi
protect
mucos
immun
respons
prime
immun
vsv
becom
well
establish
viral
vector
system
immun
given
low
preexist
antivsv
immun
human
vector
natur
tropism
mucosa
plethora
effect
vsvvector
vaccin
gener
induc
protect
humor
respons
mucos
immun
viral
diseas
includ
human
immunodefici
viru
herp
simplex
viru
human
papillomaviru
sever
acut
respiratori
syndrom
influenza
howev
studi
demonstr
great
potenti
vsv
use
vaccin
platform
potenti
elicit
antiintracellular
bacteri
immun
remain
establish
particular
vsv
never
use
purpos
antitb
vaccin
studi
engin
interferon
ifn
induc
vsv
mutant
express
explor
potenti
boost
vaccin
found
deliv
mucos
vaccin
abl
wwwmoleculartherapyorg
vol
june
boost
mucos
tcell
respons
induc
parenter
prime
immun
effect
therebi
lead
effect
protect
murin
model
pulmonari
tb
studi
therefor
suggest
vsv
vector
system
promis
candid
heterolog
boost
immun
intracellular
bacteri
infect
attenu
replic
vsv
vector
system
util
develop
vector
system
carri
mutat
viral
matrix
protein
lead
inabl
viru
block
mrna
export
nucleu
host
cell
therebi
restor
antivir
cytokin
respons
normal
limit
wildtyp
vsv
infect
featur
vector
exploit
builtin
immun
adjuvant
immun
vsv
engin
express
immunodomin
mtb
antigen
mycolyl
transferas
enzym
necessari
mycobacteri
cell
wall
synthesi
member
complex
protein
express
genet
tb
vaccin
shown
one
immunogen
mtb
antigen
place
downstream
human
tissu
plasminogen
activ
tpa
signal
peptid
allow
secret
protein
order
maxim
antigen
present
major
histocompat
complex
class
class
ii
pathway
therebi
enhanc
immunogen
antigen
transgen
clone
viral
genom
g
l
gene
figur
viral
rescu
purif
cell
infect
either
titrat
ad
express
control
cell
lysat
separ
use
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
immunoblot
probe
use
monoclon
antibodi
polyclon
vsv
antibodi
cell
express
figur
also
vsv
protein
figur
cell
singl
protein
band
detect
suggest
unprocess
form
wherea
cell
appear
two
similars
protein
band
suggest
presenc
unprocess
process
form
figur
ador
vsvinfect
cell
produc
protein
higher
molecular
weight
nativ
protein
like
due
presenc
attach
signal
peptid
posttransl
modif
infect
mammalian
cell
therefor
abl
incorpor
foreign
mtb
transgen
success
express
abund
infect
cell
determin
optim
dose
immun
order
character
vivo
balbc
mice
immun
intramuscularli
im
increas
dose
one
week
immun
mice
kill
splenocyt
stimul
ex
vivo
peptid
frequenc
occurr
cell
measur
use
enzymelink
immunosorb
spot
naiv
control
exhibit
antigenspecif
cell
data
shown
clear
differ
tcell
respons
among
dose
test
figur
although
statist
differ
level
cell
trigger
plaqu
form
unit
pfu
dose
higher
two
dose
test
figur
dose
thu
use
subsequ
experi
data
also
indic
immunogen
vivo
view
fact
remain
replicationeffici
anticip
potenti
use
respiratori
mucos
immun
use
pfu
dose
examin
extent
lung
tissu
inflamm
caus
intranas
immun
comparison
naiv
control
figur
left
panel
observ
slight
increas
cellular
within
lung
parenchyma
mice
immun
figur
right
panel
asid
modest
infiltr
overal
level
inflamm
tissu
airway
endothelium
minim
affirm
dose
deliv
mucos
minim
inflammatori
order
character
immun
compar
tcell
respons
two
differ
rout
administr
vector
balbc
mice
immun
either
parenter
im
mucos
rout
tcell
respons
analyz
airway
lumen
lung
spleen
timecours
tetram
stain
use
estim
cell
specif
immunodomin
epitop
within
follow
im
immun
antigenspecif
cell
found
mainli
lung
spleen
figur
order
examin
function
cell
cell
harvest
three
tissu
compart
stimul
tcell
peptid
intracellular
cytokin
stain
icc
carri
measur
antigenspecif
cell
distribut
tetram
cell
cell
predominantli
popul
system
tissu
im
immun
figur
c
left
panel
wherea
undetect
level
found
mucos
site
figur
left
panel
respons
appear
domin
cell
contrast
immun
mice
gener
cell
almost
exclus
airway
lumen
figur
right
panel
cell
detect
lung
interstitium
littl
system
activ
evid
spleen
follow
rout
immun
figur
c
right
panel
interest
note
contrast
effect
im
immun
greater
tcell
respons
trigger
immun
kinet
tcell
activ
result
altern
rout
immun
also
seem
differ
week
week
timepoint
peak
activ
im
administr
respect
week
later
naiv
mice
well
immun
mice
examin
lung
patholog
purpos
mice
kill
lung
section
hematoxylin
eosin
stain
repres
imag
present
immun
protect
mtb
challeng
lung
end
mice
immun
either
im
im
subcutan
administ
bcg
control
two
week
immun
mice
challeng
airway
virul
mtb
four
week
challeng
lung
analyz
bacteri
burden
observ
earlier
bcg
abl
provid
log
protect
im
provid
littl
protect
compar
naiv
mice
p
figur
imadminist
im
immun
also
provid
littl
protect
figur
contrast
confer
signific
level
protect
log
compar
naiv
imimmun
mice
p
figur
order
understand
whether
protect
tcell
respons
administ
would
sustain
mice
immun
describ
earlier
challeng
mtb
week
immun
observ
earlier
bcg
maintain
log
protect
p
figur
howev
initi
protect
provid
inadminist
observ
week
vanish
mice
challeng
week
immun
figur
data
suggest
although
immun
vsv
vaccin
provid
better
protect
im
rout
protect
rel
transient
observ
singl
immun
induc
transient
protect
immun
respons
mtb
challeng
suggest
potenti
use
standalon
vaccin
limit
reason
explor
potenti
use
booster
vaccin
report
earlier
parenter
im
immun
recombin
adenoviralvector
vaccin
express
fail
protect
lung
wherea
airway
deliveri
solubl
antigen
restor
protect
therefor
consid
possibl
immun
could
employ
boost
protect
immun
respons
local
lung
im
prime
immun
heterolog
viral
primeboost
immun
regimen
mucos
deliv
viral
booster
deposit
antigen
also
provid
inflammatori
signal
airway
cumul
approach
specif
nonspecif
recruit
antigenspecif
cell
system
pool
cell
also
use
heterolog
viral
vector
purpos
boost
circumv
problem
associ
viral
neutral
antibodi
gener
prime
immun
end
balbc
mice
prime
im
week
later
boost
administ
two
week
boost
mice
kill
number
cell
airway
lumen
lung
spleen
determin
use
tetram
immunostain
im
administr
result
cell
detect
airway
lumen
elicit
small
sizeabl
number
cell
figur
b
contrast
im
primeandboost
regimen
led
increas
number
cell
airway
lumen
compar
number
found
either
standalon
immun
figur
b
dramat
increas
cell
also
evid
lung
interstitium
approxim
tenfold
increas
mice
receiv
primeandboost
compar
imimmun
mice
increas
compar
mice
figur
c
upon
examin
effector
central
memori
tcell
surfac
marker
includ
major
cell
lung
found
effector
memori
phenotyp
data
shown
comparison
increas
cell
spleen
account
primeandboost
regimen
much
smaller
amplifi
approxim
twofold
approxim
fourfold
compar
im
respect
figur
compar
level
antigenspecif
cell
airway
lumen
lung
spleen
use
icc
differ
cell
airway
lumen
primeandboost
regimen
compar
number
cell
either
immun
administ
alon
figur
differ
lung
spleen
cell
number
differ
immun
similar
observ
use
tetram
stain
lung
primeandboost
regimen
result
approxim
tenfold
increas
tcell
number
rel
im
administr
alon
increas
rel
administr
alon
figur
although
modest
extent
nevertheless
threefold
sixfold
increas
cell
number
spleen
primeandboost
regimen
compar
cell
number
found
im
respect
figur
interest
note
boost
domin
effect
cell
result
suggest
mucos
immun
repres
power
way
boost
airway
lumin
tcell
respons
parenter
genet
immun
host
observ
robust
boost
effect
tcell
respons
examin
protect
capac
immun
protocol
challeng
week
immun
mice
immun
primeandboost
regimen
exhibit
log
protect
compar
naiv
mice
receiv
im
alon
p
figur
howev
timepoint
primeandboost
regimen
provid
compar
level
protect
lung
provid
alon
figur
provid
better
protect
system
spleen
p
figur
challeng
week
immun
mice
immun
alon
longer
protect
wherea
primeandboost
regimen
abl
maintain
log
protect
lung
p
figur
interest
note
primeandboost
regimen
afford
mice
log
protect
p
spleen
even
better
provid
bcg
figur
therefor
im
primeandin
boost
regimen
provid
better
sustain
protect
pulmonari
mtb
challeng
im
alon
comparison
sever
viral
vector
system
util
tb
vaccin
vsv
repres
attract
candid
low
incid
antibodi
vsv
gener
popul
rare
occurr
advers
outcom
follow
infect
human
basi
consider
vsv
use
gener
number
effect
antivir
vaccin
mediat
immun
induc
neutral
antibodi
recent
vsvvector
vaccin
describ
immun
malaria
yersinia
pesti
infect
howev
vsv
use
vaccin
mtb
therefor
studi
repres
first
attempt
develop
recombin
vsv
tb
vaccin
addit
understand
tcell
activ
vsvvector
vaccin
yet
fulli
establish
result
suggest
vsv
use
effect
tb
booster
vaccin
heterolog
primeandboost
regimen
although
protect
efficaci
limit
use
standalon
vaccin
although
vsv
caus
selflimit
infect
mild
tissu
inflammatori
respons
mani
speci
includ
human
vsv
infect
pathogen
mice
particularli
balbc
mice
pose
limit
vaccin
develop
use
vsv
murin
model
call
attenu
viru
varieti
method
report
attenu
vsv
employ
vsv
harbor
mutant
viral
matrix
protein
substanti
attenu
viru
addit
mutant
vsv
enhanc
capabl
induc
antivir
ifn
respons
host
cell
would
otherwis
subvert
wildtyp
vsv
infect
featur
believ
promot
downstream
adapt
immun
respons
cytokin
product
major
histocompat
complex
class
upregul
thu
exploit
builtin
immun
adjuv
current
studi
hand
strong
immun
adjuv
activ
enhanc
immunogen
heterolog
antigen
also
immun
respons
vsv
antigen
may
limit
repeat
applic
vsv
vector
host
case
adenovir
vector
system
therefor
believ
vsv
vector
hold
great
potenti
use
heterolog
vector
boost
immun
respons
trigger
prime
immun
viru
vector
ad
admittedli
vsv
use
studi
replic
viru
unlik
amen
clinic
applic
develop
replicationdefici
vsv
tb
vaccin
protect
tb
associ
strong
cellmedi
immun
respons
therefor
examin
cellular
respons
immun
import
part
investig
im
deliveri
primarili
system
respons
detect
antigenspecif
cell
popul
spleen
lung
rout
immun
appear
activ
cell
contrast
deliv
activ
antigenspecif
cell
airway
interest
note
cell
primarili
cell
gener
primari
respons
peak
week
immun
lung
spleen
peak
week
airway
lumen
distinct
distribut
profil
cell
respons
two
rout
immun
expect
system
immun
gener
system
respons
wherea
mucos
immun
lead
mucos
respons
find
agreement
data
earlier
studi
use
recombin
adenovir
tb
vaccin
differ
tcell
profil
may
fact
vsv
natur
tropic
respiratori
mucosa
better
infect
epitheli
cell
lead
increas
secret
turn
may
result
increas
tcell
activ
major
vsvvector
vaccin
develop
date
design
elicit
antivir
antibodi
respons
mucos
deliveri
vsvvector
vaccin
induct
mucos
system
neutral
antibodi
correl
protect
challeng
recent
studi
vsvvector
vaccin
pesti
also
emphas
induct
high
antibodi
titer
although
mechan
protect
remain
elucid
studi
relat
human
immunodefici
viru
first
explor
activ
system
cell
mucos
immun
vsvvector
vaccin
anoth
studi
observ
induct
system
tcell
respons
intranas
immun
vsv
vaccin
studi
examin
tcell
respons
restrict
system
compart
first
examin
mucos
tcell
immun
respons
vsvvector
immun
found
despit
modest
tcell
respons
induc
singl
immun
mice
challeng
week
later
virul
mtb
exhibit
log
protect
lung
compar
naiv
control
differ
level
protect
afford
administ
bcg
signific
contrast
im
immun
vaccin
unabl
protect
mice
mtb
challeng
previous
observ
im
deliveri
adenovir
vector
express
also
unabl
provid
signific
protect
protect
observ
mucos
immun
probabl
mediat
increas
cellular
respons
airway
lumen
earlier
shown
good
correl
protect
howev
mice
challeng
week
immun
protect
confer
singl
deliveri
disappear
probabl
wane
cellular
respons
airway
lumen
week
cell
almost
undetect
level
although
minim
number
antigenspecif
tetram
cell
could
still
observ
rel
low
level
tcell
respons
transient
protect
confer
singl
immun
reminisc
anoth
viral
vaccin
viral
vaccin
modifi
vaccinia
viru
ankara
vector
express
vector
induc
modest
tcell
respons
use
singl
deliveri
either
mucos
parenter
inde
even
two
success
intraven
administr
howev
potent
boost
effect
tcell
respons
induc
heterolog
prime
vaccin
fact
prompt
us
continu
analyz
boost
vaccin
investig
whether
boost
im
administ
mice
would
boost
memori
cell
within
airway
lumen
enhanc
protect
inde
antigenspecif
cell
profoundli
boost
airway
lumen
lung
lesser
extent
spleen
upon
challeng
mtb
mice
display
log
protect
lung
compar
naiv
control
howev
level
protect
lung
confer
primeandboost
regimen
good
confer
parenter
bcg
immun
although
level
system
protect
spleen
provid
two
regimen
compar
observ
support
continu
use
bcg
prime
vaccin
use
virusbas
vaccin
boost
nevertheless
virusbas
tb
vaccin
potenti
immun
individu
qualifi
bcg
immun
human
immunodefici
virusinfect
children
may
argu
multipl
heterolog
booster
vaccin
may
requir
maintain
protect
immun
mtb
throughout
human
lifetim
demonstr
abil
boost
bcg
prime
immun
boost
immun
confer
lend
support
adopt
immun
regimen
bcg
prime
repeat
advsv
boost
mice
sixto
tenweekold
femal
balbc
mice
purchas
harlan
laboratori
hous
specif
pathogenfre
level
b
facil
experi
carri
accord
anim
research
ethic
board
mcmaster
univers
recombin
replicationdefect
ad
express
mtb
gener
purifi
describ
earlier
order
construct
link
human
tpa
signal
peptid
pcramplifi
shuttl
plasmid
use
forward
primer
introduc
upstream
sali
restrict
site
revers
primer
introduc
downstream
nhei
restrict
site
site
underlin
pcr
product
digest
sali
nhei
purifi
ligat
pvsvxndg
plasmid
digest
xhoi
nhei
creat
pvsvxndg
follow
transform
escherichia
coli
cell
recombin
plasmid
recov
analyz
sequenc
mobix
mcmaster
univers
order
verifi
correct
largescal
purif
plasmid
cotransfect
helper
plasmid
rescu
viru
viru
subsequ
amplifi
purifi
titer
accord
standard
protocol
immunoblot
order
verifi
protein
express
infect
cell
infect
viru
multipl
infect
addit
cell
infect
multipl
infect
timepoint
hour
infect
respect
cell
lysat
two
batch
harvest
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
load
buffer
mmoll
triscl
ph
mmoll
dithiothreitol
sodium
dodecyl
sulfat
bromophenol
blue
glycerol
togeth
complex
sampl
run
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
gel
transfer
nitrocellulos
membran
probe
monoclon
antibodi
clone
membran
incub
horseradish
peroxidaseconjug
secondari
antibodi
protein
detect
use
ecl
film
kodak
membran
subsequ
incub
polyclon
vsv
antibodi
follow
incub
alexa
fluor
secondari
antibodi
protein
detect
use
odyssey
machin
immun
prepar
phosphatebuff
salin
dose
pfu
pfu
pfu
indic
deliv
either
im
rout
im
immun
viru
prepar
volum
mice
lightli
anesthet
inoculum
administ
two
quadricep
immun
viru
prepar
volum
mice
lightli
anesthet
allow
inhal
volum
viru
administ
slowli
pipett
tip
challeng
experi
mice
immun
bcg
connaught
strain
bcg
prepar
describ
later
section
dose
coloni
form
unit
phosphatebuff
salin
mice
lightli
anesthet
innoculum
administ
two
hind
quarter
lung
histolog
isol
lung
submerg
formalin
fix
tissu
tissu
process
section
stain
hematoxylin
eosin
tissu
sampl
view
magnif
mice
kill
immun
order
examin
immunogen
spleen
lung
isol
process
previous
describ
singlecel
suspens
gener
sampl
incub
red
blood
cell
wwwmoleculartherapyorg
vol
june
lysi
buffer
minut
r
system
minneapoli
mn
airway
lumin
cell
isol
lung
exhaust
lavag
describ
earlier
cell
tissu
enumer
resuspend
complet
roswel
park
memori
institut
seed
plate
ex
vivo
antigen
stimul
cell
plate
either
ltselpgwlqanrhvkptg
mpvggqsst
tcell
peptid
concentr
enzymelink
immunosorb
spot
assay
splenocyt
examin
order
determin
frequenc
occurr
lymphocyt
describ
earlier
splenocyt
plate
duplic
either
stimulu
peptid
hour
spot
enumer
use
elispot
counter
immunospot
softwar
immunostain
carri
order
determin
presenc
antigenspecif
cell
cytokinesecret
effector
describ
earlier
two
million
spleen
lung
cell
seed
plate
airway
lumin
cell
divid
equal
well
condit
requir
examin
icc
cell
cultur
stimulu
peptid
describ
earlier
section
hour
antibodi
use
stain
icc
cychrom
phycoerythrin
allophycocyanin
bd
pharmingen
tetram
stain
unstimul
cell
stain
immunodomin
tcell
peptid
mpvggqsst
bound
balbc
major
histocompat
complex
class
allel
conjug
phycoerythrin
texa
univers
cychrom
allophycocyanin
bd
pharmingen
san
diego
ca
stain
cell
run
lsrii
flow
cytomet
event
collect
per
sampl
depend
tissu
fluorescenceactiv
cell
sort
data
analyz
use
flowjo
softwar
tree
star
ashland
mycobacterium
bovi
bcg
connaught
strain
mtb
strain
cultur
prepar
describ
earlier
challeng
experi
mice
infect
coloni
form
unit
mtb
level
iii
contain
facil
mcmaster
univers
bacteri
burden
lung
spleen
assess
present
log
coloni
form
unit
per
organ
describ
earlier
statist
statist
analysi
carri
use
unpair
student
ttest
verifi
use
analysi
varianc
tukey
test
differ
consid
signific
p
